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Abstract
Introduction: The study aimed to evaluate the psychological profile of patients with acromegaly in comparison to other chronic diseases 
such as non-functioning pituitary adenomas, Cushing disease, and plaque psoriasis, and to a healthy control group.
Material and methods: A total sample of 153 participants in clinical groups underwent a cross-sectional assessment including the quality 
of life (AcroQoL, WHOQoL-BREF), psychiatric morbidity (GHQ-28), and the acceptance of illness (AIS), as well as 65 participants in the 
healthy control group.
Results: The whole study sample had a predominance of urban married females (61%) with medium level of education (41%). Patients 
with acromegaly were diagnosed significantly later than patients from other clinical groups, after the onset of the first symptoms. Ac-
romegaly was related to the presence of more symptoms of anxiety and insomnia, and poorer social relationships compared with the 
general population but not more than in other chronic diseases. 
A better quality of life score in all domains of WHOQoL-BREF was associated with a better score on the acceptance of illness scale and 
lower scores on GHQ-28.
Conclusions: Psychiatric morbidity, mainly anxiety and insomnia, occurs in 50% of patients with acromegaly. However, the psychological 
wellbeing and mood seem to be related to other factors such as the acceptance of the illness. Thus, concerning the diagnosis, treatment, 
and monitoring of acromegaly an interdisciplinary approach, taking into account psychological and psychiatric consultation, is needed. 
(Endokrynol Pol 2017; 68 (5): 524–532)
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Streszczenie
Wstęp: Celem pracy była ocena profilu psychologicznego pacjentów z akromegalią w porównaniu z pacjentami z innymi chorobami 
przewlekłymi, takimi jak: nieczynne hormonalnie gruczolaki przysadki, choroba Cushinga, łuszczyca oraz zdrowych z grupy kontrolnej.
Materiał i metody: Badaniem objęto 153 chorych w grupach klinicznych, którzy zostali poddani szerokiej ocenie obejmującej: jakość życia (AcroQoL, 
WHOQoL-BREF), występowanie zaburzeń psychiatrycznych (GHQ-28) i stopień akceptacji choroby (AIS) oraz 65 uczestników z grupy kontrolnej.
Wyniki: W całej grupie badanej obserwowano przewagę zamężnych, miejskich kobiet (61%) z wykształceniem średnim (41%). Pacjenci 
z akromegalią byli diagnozowani znacznie później w stosunku do pozostałych grup chorych, po pojawieniu się pierwszych objawów. 
Akromegalia charakteryzowała się częstszym występowaniem bezsenności i lęku oraz gorszymi relacjami społecznymi w porównaniu 
z populacją ogólną, ale nie w stosunku do innych chorób przewlekłych. Lepsza jakość życia we wszystkich domenach formularza WHO-
QoL-BREF wiązała się z większą akceptacją choroby i niższym wynikiem w skali GHQ-28.
Wnioski: Zaburzenia psychiatryczne, głównie lęk i bezsenność, występują u 50% pacjentów z akromegalią. Jednak stan psychiczny i nastrój wy-
dają się związane z innym czynnikiem, jakim jest stopień akceptacji choroby. Podkreśla to potrzebę opieki interdyscyplinarnej, uwzględniającej 
opiekę psychiatryczną i psychologiczną, w diagnostyce, leczeniu i monitorowaniu pacjentów z akromegalią. (Endokrynol Pol 2017; 68 (5): 524–532)
Słowa kluczowe: akromegalia, choroba przewlekła, jakość życia, psychopatologia
Introduction
Acromegaly is a rare, chronic disease with an incidence 
rate of 3–4 cases per million, caused by excessive pro-
duction of growth hormone (GH) as a result of a pitui-
tary adenoma in almost all cases [1, 2]. According to 
most studies, patients with acromegaly have impaired 
quality of life (QoL) due to the chronic nature of the 
Dorota Szcześniak, Division of Consultation Psychiatry and Neuroscience, Department of Psychiatry Wroclaw Medical University Pasteura 10, 
50–367 Wroclaw, Poland, e-mail: dorota.szczesniak@umed.wroc.pl
525
Endokrynologia Polska 2017; 68 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
disease, the burden of comorbidities, and, potentially, 
the burden of therapy [3, 4]. With references to the 
guidelines, not only biochemical parameters but also 
the improvement of the QoL should be considered in 
clinical practice as tools to assess the success in acro-
megaly treatment [6, 7]. Normalisation of GH and IGF-1 
(insulin-like growth factor-1) levels and their relation 
to better QoL is still debatable [8–12]. The research 
emphasises that the QoL correlates with variables such 
as age, duration of the disease, treatment, presence of 
other symptoms, disease activity, and gender. Female 
gender, older age, macroadenomas, and radiotherapy 
correlate with a lower QoL [11, 13]. Moreover, depres-
sion and anxiety seem to have a greater impact on 
the QoL than the biochemical parameters [14]. Long 
lasting endocrine diseases in general are frequently 
associated with a wide range of psychological distress, 
which often reach the level of psychiatric morbidity. 
Irritable mood occurred in 46% of patients successfully 
treated for endocrine conditions, a rate similar to that 
found in cardiological diseases and higher than in on-
cological and gastroenterological diseases [15]. Among 
all patients with pituitary adenoma, the patients with 
remitted Cushing’s disease demonstrate the smallest 
improvement of QoL after the treatment [16]. There are 
not many papers comparing the QoL in acromegaly and 
other chronic diseases; however, one of them shows no 
significant difference between acromegalics and other 
patients suffering from cardiovascular diseases, malig-
nancies, rheumatic diseases, and chronic pulmonary 
obstruction [13].
The aim of this study was to evaluate the QoL, the 
acceptance of illness, and the psychopathological status 
in patients with acromegaly in a cross-sectional manner 
in comparison with those suffering from other severe 
chronic diseases affecting the QoL.
Materials and Methods
Setting and design
A comparative, cross-sectional cohort study was con-
ducted at the Department of Endocrinology, Diabetes, 
and Isotope Therapy and the Department of Derma-
tology, Venerology, and Allergology, Wroclaw Medical 
University during the years 2012–2015.
Sample
Two hundred and eighteen participants were enrolled 
in the study. All the participants were recruited on the 
basis of written, informed consent assuring confidenti-
ality and freedom of choice of the participation. The Re-
search Ethics Committee of Wroclaw Medical University 
had approved the study. The purposive sample com-
prised five groups. Three research groups composed of 
pituitary adenomas patients: 1. acromegaly patients (A), 
n = 50; 2. Cushing disease patients (CD), n = 15; and 
3. non-functioning pituitary adenoma patients (NFPA), 
n = 37. There were two control groups included in the 
study. A group of chronic disease: 4. psoriasis patients 
(P), n = 51; and 5. a group of healthy controls (HC), n = 
65 recruited from the attendants/relatives of the patients 
and volunteers. The rationale for the inclusion in the 
study different groups is the willingness to compare 
QoL of patients diagnosed with pituitary adenomas 
with different consequences such as changes in appear-
ance (A, CD) or without these changes (NFPA), and with 
patients chronically ill with visual changes in the ap-
pearance resulting from non-endocrine disease (P). The 
clinical groups included patients of both genders and 
age range 19–87 years. That choice of the study group 
was strictly connected with the observation character 
of the analyses and emphasising the problem of living 
with chronic disease. Therefore, the authors decided not 
to introduce any additional divisions into subgroups 
considering the degree of disease severity. In case of 
acromegaly, the subjects are patients with active acro-
megaly (n = 32) as well as patients with somatostatin 
analogue-controlled disease (n = 18).
Acromegaly was diagnosed based on clinical and 
biochemical parameters by nadir serum GH after an oral 
glucose tolerance test (OGTT) 0.4 ng/mL, and elevated 
IGF-1 for age and gender. Age and sex-normalised 
levels of IGF-1, associated with nadir GH after OGTT 
< 0.4 ng/mL after surgery and random GH < 1 ng/mL 
when treated with somatostatin analogues, are taken as 
a criterion of cure or good disease control [6, 7, 17, 18].
The diagnosis of CD was based on the clinical signs 
and standard hormonal criteria: increased urinary 
excretion of UFC (urinary free cortisol), loss of corti-
sol circadian rhythm, and failure of serum cortisol to 
suppress below 1.8 µg/dl (50 nmol/L) during low-dose 
dexamethasone suppression tests (DST 1 mg overnight 
or LDDST; 2 mg/day over 48 hours). The pituitary aeti-
ology of CD was confirmed basing on a serum cortisol 
and UFC suppression greater than 50% on a high-dose 
dexamethasone suppression test (HDDST; 2 mg q.i.d. 
for 48 h), an inappropriately normal or increased ACTH 
level (above 20 pg/mL), and positive MRI. The criteria 
for remission were: serum cortisol within the referral 
range, normal circadian rhythm, and the ability of 
serum cortisol to suppress to values < 1.8 µg/dL after 
DST 1 mg overnight [19–21]. Patients with NFPA did 
not present any symptoms of classical clinical hormone 
excess syndrome. They presented effects of mass (visual 
fields defect, headache, and deficiencies of pituitary 
hormones). The diagnosis is usually late, in a stage of 
macroadenomas, mostly with invasion of the adjacent 
structures. Transsphenoidal surgery is rarely curative, 
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and tumour residue can regrow in as many as 65% of 
patients during long-term follow-up [22, 23]. 
The diagnosis of psoriasis was made according to 
the well-established clinical criteria, including sharply 
demarcated round-oval erythematous plaques with 
loosely adherent silvery-white scales, especially affect-
ing the elbows, knees, lumbosacral area, intergluteal 
cleft, and scalp. The clinical extent of disease and its 
impact on QoL was based on PASI (Psoriasis Area 
Severity Index), BSA (Body Surface Area), and DLQI 
(Dermatology Life Quality Index) [24, 25]. All of the 
studied subjects fulfilled the criteria for moderate-to- 
-severe psoriasis as defined by PASI and BSA (14.4 ± 6.7 
points and 23.7 ± 16.3%, respectively). The mean DLQI 
score was assessed as 11.6 ± 6.4 points, which reflects 
a very large effect on the patient’s life. The rest of sub-
jects’ characteristics are summarised in Table I.
Instruments
The following instruments were used in the patient 
groups:
1. A sociodemographic profile sheet.
2. A clinical profile sheet for different clinical groups, 
used to record the following clinical details: disease 
onset and duration, delay of diagnosis, first symp-
toms, treatment, comorbidities, and illness-related 
characteristics (e.g. IGF-1 level, GH level, PASSI, 
BSA).
3. The 26-item Polish version of the WHO Quality 
of Life Scale-BREF (WHOQoL-BREF) [26, 27]. It 
profiles the subjective evaluation of the QoL in the 
past two weeks for four domains: physical health 
(PhyHealth), psychological health (PsyHealth), 
social relationship SocRel), and environment 
(Enviro). 
Table I. Demographic characteristics of the study groups
Tabela I. Charakterystyka grup badanych
A  
(n = 50)
CD  
(n = 15)
NFPA  
(n = 37)
P  
(n = 51)
HC  
(n = 65)
 p-value
Gender (females) n (%) 31 (62%) 14 (93%) 27 (73%) 19 (37%) 42 (65%) CD vs P
NFPA vs P
HC vs P
p = 0.0002
p = 0.001
p = 0.005
Age (mean years ± 
SD)
51.7 ± 14.5 45.1 ± 13.92 48.9 ± 15.42 42.3 ± 13.3 44.8 ± 16.1 A vs P p = 0.01
Education 
n (%)
low 4 (8%) – 2 (5%) – 2 (3%)
medium 31 (62%) 8 (53%) 25 (68%) 33 (65%) 57 (53%)
high 14 (38%) 7 (47%) 10 (27%) 17 (33%) 27 (42%)
unknown 1 (2%) – – 1 (2%) 1 (2%)
Locality of living n (%)
city 35 (70%) 11 (73%) 6 (16%) 31 (61%) 53 (82%)
country 15 (30%) 4 (27%) 31 (84%) 19 (37%) 12 (18%)
unknown – – – 1 (2%) –
Time since diagnosis 
(in years)
8.4 ± 8.8
 
6.4 ± 8.0 7.4 ±9.1 17.7 ±11.7 – A vs. P
CD vs. P
NFPA vs. P
p = 0.0009
p = 0.002
p = 0.0002
The duration since first 
symptoms to diagnosis 
n (%)
A vs. CD
A vs. NFPA
A vs. P
p = 0.03
p = 0.002
p = 0.0002
< 6 months 4 (8%) 4 (27%) 15 (42%) 23 (45%) –
6–12 months 0 (0%) 5 (33%) 5 (14%) 7 (14%) –
1–3 years 8 (17%) 3 (20%) 3 (8%) 8 (16%) –
3–5 years 9 (19%) 1 (7%) 0 (0%) 1 (2%) –
5–10 years 12 (25%) 0 (0%) 8 (22%) 0 (0%) –
>10 years 15 (31%) 2 (13%) 5 (14%) 12 (24%) –
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4. The 28-item version of the General Health Question-
naire [28] in Polish adaptation [29]. The scale was 
used to measure the general health status and its 
four components: A — GHQ-somatic symptoms, 
B — GHQ-anxiety and insomnia, C — GHQ-social 
dysfunction, and D — GHQ-severe depression. 
Higher scores indicate a greater probability of psy-
chiatric distress. 
5. The eight-item Acceptance of Illness Scale (AIS) in 
Polish adaptation [30]. Higher scores indicate a bet-
ter illness acceptance.
Procedure
An endocrinologist and a dermatologist confirmed the 
diagnosis and carried out the initial recruitment and 
assessment using sociodemographic and clinical profile 
sheets. Thereafter, the psychologist administered all the 
instruments indicated above. Additionally, the subjects 
for the control group were recruited (Figure 1).
Statistical analysis
The values of quantitative variables are presented by 
specifying the mean value ± standard deviation. Ca-
tegorical variables are described by the percentage dis-
tribution of the occurrence of their individual values. Pa-
rameter distributions were assessed using Shapiro-Wilk 
test. In the case of categorical and quantitative variables 
the comparison of two groups was performed by using 
nonparametric Mann-Whitney test. Comparison of more 
than two groups was performed by Kruskall-Wallis test. 
A post hoc test was conducted to verify the existence 
of each intergroup difference. The study of differences 
between the two groups in terms of the distribution of 
qualitative variables was based on Pearson’s chi-square 
test, and in the case of simultaneous comparisons of 
many groups Bonferroni correction to the p-value was 
applied. An examination of the relationship between 
quantitative and ordinal variables was based on Spear-
man’s correlation rank test. As statistically significant, 
p value on the level below 0.05 was used.
The statistical analysis was done on the basis of 
Statistica for Windows version 8.0 and R packet.
Results
Study groups characteristics
A participants’ characteristics are detailed in Table I. The 
study groups (A, CD, NFPA) and the control groups 
(P, HC) had dissimilar sociodemographic profiles in 
terms of age in years and gender, but the statistical 
analysis showed that in this study these were not influ-
encing factors. The sociodemographic profiles in terms 
of education, place of residence, and marital status did 
not differ significantly between groups.
The whole study sample had a predominance of 
urban married females (61%) with a medium level of 
education (41%). The disease duration in the clinical 
groups did not differ significantly among endocrine suf-
ferers. Only the psoriasis patients were characterised by 
a longer period of disease duration onset compared to 
other groups (Table I). The distribution of time from the 
first symptoms to the diagnosis varied significantly in 
between-group comparison. Patients with acromegaly 
were diagnosed significantly later after the onset of the 
first symptoms compared to the other groups. 
The relationship between QoL, sociodemographic, 
clinical, and psychological factors
No correlation existed between the psychological and 
the sociodemographic factors. However, in acromegaly 
a relationship between psychopathological symptoms 
and gender was observed. Women had a greater ten-
dency to develop psychopathological symptoms meas-
ured by the GHQ-28 (Z = 1.96872, p = 0.05).
The duration of illness was an associated factor in 
the clinical groups. The longer patients experienced 
chronic disease, the worse were their results in the 
Illness Acceptance Scale (r = –0.2, p = 0.03), but they 
showed fewer psychopathological symptoms (GHQ- 
-28: r = –0.3, p = 0.002). In patients with acromegaly 
and in those with CD, no correspondence between 
the duration of illness and studied variables was ob-
served. In patients with NFPA a negative correlation 
between the duration of illness and the occurrence of 
psychosomatic symptoms (GHQ-A: r = –0.3, p = 0.047) 
and disorders in social sphere (GHQ-C: r = –0.3, 
p = 0.048) was observed. The longer time of experienc-
ing disease in patients with psoriasis correlated with 
the lower incidence of pathological symptoms in terms 
of anxiety and insomnia (GHQ-B: r = –0.34, p = 0.03).
The relationship between various QoL domains 
and acceptance of illness and the existence of psycho-
pathological symptoms is shown in Table II. A better 
QoL score in all was associated with a better acceptance 
of illness and less psychiatric distress (GHQ-28). The 
strongest correlation was observed between psycho-
logical health (QoL) and acceptance of illness.
In acromegaly, the acceptance of illness was related to 
the QoL in the domains of psychological health and the 
environment. The physical health domain was related 
to the acceptance of illness only among NFPA patients. 
Moreover, there was a very consistent pattern of cor-
relations between QoL and psychiatric distress. The 
strongest correlation was observed among patients with 
CD in all domains measured with WHOQoL-BREF. In 
patients with NFPA the psychiatric distress was related to 
physical and psychological health, in psoriasis with social 
relationships. In acromegaly, the psychological health 
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Table II. Correlations between WHOQoL-BREF scores and AIS and GHQ-28 scores in clinical groups
Tabela II. Korelacja pomiędzy WHOQoL-BREF (WHO Quality of Life Scale-BREF), AIS (Acceptance of Illness Scale) oraz 
GHQ-28 (General Health Questionnaire-28) w badanych grupach
Variables AIS GHQ-28
WHOQoL-BREF Groups Spearman R p-value Spearman R
Physical Health All 0.225 0.005 –0.311
Acromegaly 0.212 0.139 –0.213
CD 0.457 0.100 –0.653
NFPA 0.341 0.04 –0.553
Psoriasis 0.163 0.254 –0.216
Psychological Health All 0.436 0.000 –0.339
Acromegaly 0.343 0.02 –0.304
CD 0.387 0.172 –0.765
NFPA 0.539 0.001 –0.492
Psoriasis 0.332 0.02 –0.359
Social Relation All 0.184 0.02 –0.307
Acromegaly 0.202 0.160 –0.017
CD 0.079 0.789 –0.686
NFPA 0.144 0.394 –0.151
Psoriasis 0.070 0.623 –0.508
Environmental All 0.280 0.000 –0.343
Acromegaly 0.361 0.01 –0.281
CD 0.291 0.313 –0.637
NFPA 0.261 0.118 –0.292
Psoriasis 0.163 0.252 –0.392
Figure 1. Flow diagram of study procedure
Rycina 1. Schemat procedury badania
529
Endokrynologia Polska 2017; 68 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
and environmental domains were also associated with 
psychiatric distress, but the correlation was rather weak.
Quality of life and psychopathological status
The comparison of the QoL and psychiatric distress 
among the five groups is presented in Table III. Patients 
with acromegaly had significantly poorer QoL in social 
relations compared with healthy controls; however, 
these were still significantly better than in patients 
with psoriasis. Moreover, patients with acromegaly 
suffered more from anxiety and insomnia compared 
with healthy controls (Table III).
Figure 2 illustrates the percentage distribution 
in five study groups, in terms of the existence and 
absence of psychopathological symptoms (GHQ+/-). 
There were significant differences in the prevalence of 
psychopathological symptoms among CD and the HC 
groups (p = 0.009) and NFPA and HC (p = 0.01). The 
prevalence of psychopathological symptoms among 
acromegaly and psoriasis patients did not differ sig-
nificantly compared to the HC.
Taking into account all chronic disease subjects the 
GHQ+ subgroup had significantly poorer QoL in the 
domains of physical health (Z = 3.9534, p = 0.00001), 
psychological health (Z = 3.8916, p = 0.0001), social rela-
tionship (Z = 3.5828, p = 0.0003), environmental factors 
Table III. Quality of life and psychopathological status of study participants
Tabela III. Jakość życia i objawy psychopatologicznne badanych grup
WHOQoL-BREF A (n = 50) 
Mean ± SD
CD (n = 15) NFPA (n = 37) P (n = 51) HC (n = 65) p-value
Physical Health 55.28 ± 9.6 48.57 ± 12.9 56.11 ± 13.4 56.37 ± 12.3 60.48 ± 7.5 HC vs. CD p = 0.009
Psychological Health 63.98 ± 10.9 52.86 ± 17.3 66.24 ± 11.2 55.12 ± 14.6 69.28 ± 8.6 A vs. P
HC vs. CD
NFPA vs. P
HC vs. P
p = 0.03
p = 0.002
p = 0.005
p = 0.00000
Social Relation 69.40 ± 17.8 58.14 ± 24.4 69.95 ± 18.2 61.65 ± 21.6 79.40 ± 11.9 HC vs. A
HC vs. CD
HC vs. NFPA
HC vs. P
p = 0.006
p = 0.01
p = 0.04
p = 0.000002
Environmental 69.82 ± 14.7 62.64 ± 14.7 67.05 ± 17.3 66.08 ± 14.2 69.72± 11.7
GHQ-28 5.50 ± 5.8 9.53 ± 8.0 7.73 ± 7.2 4.59 ± 6.7 2.63 ± 3.5 HC vs. CD
HC vs. NFPA
p = 0.02
p = 0.002
A — somatic 
symptoms
1.60 ± 2.1 2.86 ± 2.6 2.57 ± 2.0 1.39 ± 2.1 0.91 ± 1.4 P vs. NFPA
HC vs. NFPA
p = 0.03
p = 0.001
B — anxiety and 
insomnia
2.16 ± 2.0 3.13 ± 2.5 2.68 ± 2.6 1.47 ± 2.1 0.97 ± 1.3 P vs. NFPA
HC vs. A
HC vs. CD
HC vs. NFPA
p = 0.03
p = 0.03
p = 0.03
p = 0.02
C — social 
dysfunction
1.10 ± 1.6 1.60 ± 1.7 1.84 ± 2.2 0.94 ± 1.6 0.45 ± 0.9 HC vs. CD
HC vs. NFPA
p = 0.05
p = 0.005
D — severe 
depression
0.62 ± 1.2 2.00 ± 2.3 1.15 ± 1.9 0.78 ± 1.5 0.32 ± 0.9 HC vs. CD P = 0.03
Figure 2. The GHQ positive/negative percentage distribution in 
study groups
Rycina 2. GHQ pozytywny/negatywny rozkład w badanych 
grupach
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(Z = 3.8541, p = 0.0001), and acceptance of the illness 
(Z = 2.1530, p = 0.03). Interestingly, the acromegaly 
patients were the only group in whom the existence 
of the psychopathological symptoms was the same 
independently of patients’ QoL and the acceptance of 
the disease (Table IV).
Acceptance of illness
The level of the acceptance of illness in four clinical 
groups is illustrated in Figure 3. The highest scores in 
terms of the acceptance of illness were obtained by pa-
tients with acromegaly and NFPA (31.96 ± 7.9 and 31.49 
± 8.0, respectively). The post hoc multiple comparisons 
test demonstrated a significant difference among pa-
tients with acromegaly and psoriasis (p = 0.009), and 
NFPA patients and psoriasis (p = 0.04).
Discussion
This is the first study evaluating psychiatric morbidity 
and QoL in patients with acromegaly, compared to 
other chronic diseases and healthy controls in Poland. 
The crucial finding is that patients with acromegaly 
scored worse in the social relation domain compared 
with the general population; however, the social 
dysfunctions did not differ significantly from those 
with other pituitary adenoma patients. The results 
pointed out the significantly higher symptomatology 
of anxiety and insomnia in patients with acromegaly 
compared to healthy controls, but still the results 
did not differ from those from other clinical groups. 
Interestingly, acromegaly patients had significantly 
greater QoL in psychological health than, for exam-
ple, psoriasis patients. This result could be surprising 
because some previous studies showed that QoL in 
acromegaly is impaired not only in comparison with 
the general population but also with other chronic 
diseases such as asthma, angina, or osteoarthritis [5]. 
However, the highest psychopathological symptoma-
tology and the lowest QoL are the characteristics of 
patients with CD. There are also observed: cognitive 
function impairment, circadian rhythm disturbances, 
and sleeping disorders. CD sometimes causes psy-
chotic symptoms as a consequence of vasogenic and 
metabolic damage of brain structures and cerebral at-
rophy. The result of these complications is a decreased 
quality of life [31].
In this study, no correlation existed between psy-
chological and psychopathological variables and the 
sociodemographics. Only acromegalic women had 
a greater tendency to develop the psychopathological 
symptoms, which is consistent with some previous stud-
ies [15, 32] but different from another study that showed 
more depression and distress in acromegalic males [33].
The prevalence of psychopathological symptoms 
among acromegaly patients did not differ signifi-
cantly compared to healthy controls; however, the 
tendency towards mental morbidity was twice as high. 
A 35% prevalence of mental disorders in acromegaly 
was shown in a study from India [34], and a 62.5% 
prevalence of depression was observed in a Spanish 
sample [35]. In our study, a 50% prevalence of psychi-
atric distress was observed, most frequently occurring 
with anxiety and insomnia. The same observations 
were shown in a study from Germany. Sievers et 
al. (2009) showed that acromegalic patients suffered 
more from anxiety and they were more neurotic and 
had higher levels of pessimism, asthenia, and fatigue 
compared with healthy controls [35]. In our study, 
we observed significant differences in the prevalence 
of psychopathological symptoms (psychosomatic, 
anxiety, insomnia, and social dysfunction) among CD 
and HC, and NFPA and HC. In the CD group, we also 
observed a greater occurrence of severe depression. 
Miller et al. (2008) compared acromegaly, NFPA pa-
tients, and healthy subjects, and they did not observe 
any differences between acromegalics and the other 
two groups in terms of mental health and emotional 
status, but NFPA patients had worse scores in physical 
and social functioning and general health compared 
to acromegaly [36].
This study is the first one that addressed the accept-
ance of illness issues among patients with pituitary 
adenomas, which seems to be a significant correlate 
of QoL, as well as of psychopathological symptoms 
regardless the type of chronic disease. A correlation 
between the QoL and the acceptance of illness among 
all participants was observed. A better QoL score was 
associated with a better acceptance of illness and less 
Figure 3. Acceptance of illness in clinical groups
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psychopathology, which should result in the inter-
disciplinary approach to a chronic disease, including 
psychological assessment. 
Another important point deriving from this study 
is that patients with acromegaly are diagnosed sig-
nificantly later, counting from the onset of the first 
symptoms, compared to patients from other clinical 
groups. 31% of the acromegaly patients had waited for 
diagnosis for more than 10 years. This finding is associ-
ated with the risk of uncontrolled development of the 
disease symptoms without implementing any treating 
standards, and hence to the development of the nega-
tive consequences associated with acromegaly.
The limitations of this work should be listed, includ-
ing the cross-sectional study design, because the aim 
was to describe a population of chronic disease patients 
mainly focused on acromegaly, and not to make causal 
inference. Nevertheless, our results seem to be useful 
for public health planning and understanding disease 
psychopathological consequences and the role of indi-
vidual psychological factors in the treatment process. 
What is more, the study groups were not matched con-
cerning age and gender, but as the statistical analysis 
showed these factors transpired to be not influencing. 
Another limitation is not taking into account the medi-
cal history and biochemical parameters, which accord-
ing to previous studies are relevant. However, due to 
the fact that the study sample consisted of various 
clinical subgroups, the authors decided to reduce the 
evaluation to psychological variables and the psycho-
pathological status of patients.
Conclusions
The main findings were that acromegaly is related to 
higher symptomatology of anxiety and insomnia, and 
poorer social relationships compared with the general 
population but comparable to or even greater than 
in other severe chronic diseases. Interestingly, other 
QoL domains such as psychological, physical, and 
environmental do not differ from healthy controls. 
This may be connected with the acceptance of illness, 
which in our sample was rather high, and which seems 
to have a significant impact on the QoL, as well as on 
psychopathological symptoms. In the treatment pro-
cess beyond the control of biochemical parameters the 
components of mental health associated with mood 
and the level of acceptance of the disease are crucial. 
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